Cardiovascular Diseases Clinical Trial
— TRISCEND JAPANOfficial title:
Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System: Investigation of Safety and Clinical Efficacy Using a Novel Device in Patients With at Least Severe Tricuspid Regurgitation in JAPAN
A prospective, open, non-randomized, multicenter, clinical trial to evaluate the safety and effectiveness of the Edwards EWJ-202 transcatheter tricuspid valve replacement system in the treatment of patients with at least severe tricuspid regurgitation despite medical therapy. Subjects will be followed at discharge, 30 days, 6 months and annually through 5 years.
Status | Recruiting |
Enrollment | 45 |
Est. completion date | April 30, 2029 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Symptomatic tricuspid regurgitation (TR) despite medical therapy - TR graded as severe or greater - Appropriate for transcatheter tricuspid valve replacement per the local heart team Exclusion Criteria: - Tricuspid valve anatomic contraindications - Need for emergent or urgent surgery or any planned cardiac surgery within the next 12 months - Hemodynamic instability - Refractory heart failure requiring advanced intervention - Currently participating in another investigational study |
Country | Name | City | State |
---|---|---|---|
Japan | Tokai University Hospital | Isehara-shi | Kanagawa |
Japan | Kokura Memorial Hospital | Kitakyushu-shi | Fukuoka |
Japan | Osaka Police Hospital | Osaka-shi | Osaka |
Japan | Sendai Kousei Hospital | Sendai-shi | Miyagi |
Japan | Keio University Hospital | Shinjuku-Ku | Tokyo |
Japan | Tokyo Women's Medical University Hospital | Shinjuku-Ku | Tokyo |
Japan | Osaka University Hospital | Suita | Osaka |
Japan | National Cerebral and Cardiovascular Center | Suita-shi | Osaka |
Lead Sponsor | Collaborator |
---|---|
Edwards Lifesciences |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | All-Cause Mortality | Participants with all-cause mortality at 1 year from the index procedure | 1 year | |
Primary | Heart Failure Hospitalization | Participants with a heart failure hospitalization at 1 year from the index procedure | 1 year | |
Secondary | Rates of various adverse events | Rates of various adverse events as defined in the protocol | 30 days, 6 months, 12 months, annual for five years | |
Secondary | Rate of Major Adverse Events (MAEs) | Composite rate of MAEs as defined in the protocol | 30 days | |
Secondary | Reduction in TR grade | Number of participants with reduction in TR from baseline | 30 days, 6 months, 12 months, annual for five years | |
Secondary | New York Heart Association (NYHA) Functional Class | Number of participants with improvement in NYHA class | 30 days, 6 months, 12 months, annual for five years | |
Secondary | Health Status as measured by the SF-36 Questionnaire | Number of points of improvement in health status as measured by 36-item short form survey (SF-36) | 30 days, 6 months, 12 months, annual for five years | |
Secondary | Health Status as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) | Number of points of improvement in health status as measured by KCCQ | 30 days, 6 months, 12 months, annual for five years | |
Secondary | Health Status as measured by the EQ-5D-5L Questionnaire | Number of points of improvement in health status as measured by EQ-5D-5L Questionnaire | 30 days, 6 months, 12 months, annual for five years | |
Secondary | Six-minute walk test | Change in distance (m) from baseline | 30 days, 6 months, 12 months, annual for five years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|